Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06420752 · ClinicalTrials.gov registry record · Phase 2
Passive Stretching in Peripheral Arterial Disease Patients
A Phase 2 study of Inflammation and Peripheral Arterial Disease, sponsored by University of Wisconsin, La Crosse.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06420752: Recruiting Phase 2 study of Inflammation and Peripheral Arterial Disease, sponsored by University of Wisconsin, La Crosse.
NCT06420752 is a Phase 2 study of Inflammation and Peripheral Arterial Disease that is actively recruiting participants, run by University of Wisconsin, La Crosse. The registered enrollment target is 64 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06420752, a Phase 2 study of Inflammation and Peripheral Arterial Disease, is actively recruiting participants, sponsored by University of Wisconsin, La Crosse.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Peripheral artery disease (PAD) leads to higher mortality rates and strains healthcare systems due to increased costs. It causes leg pain during walking due to reduced blood flow. Nitric oxide (NO) deficiency contributes to vascular issues in PAD, with few effective treatments available. Passive calf muscle stretching boosts NO levels, vascular health, and walking ability in PAD patients. However, the inflammatory processes underlying these improvements are unclear. This study aims to track inflammatory markers and cardiovascular changes during 12 weeks of passive stretching. Additionally, combining stretching with dietary nitrate could further enhance walking capacity by reducing reactive oxygen species. The study will monitor inflammation, vascular function, and oxidative capacity to understand the effects on functional ability in PAD patients. This research is crucial for improving physical function and addressing exercise intolerance in PAD.
Primary Outcome
6-minute walking distance will be assessed prior to an at various time points during the 12-week study
Conditions Studied
Interventions
- DEVICE Calf Plantar flexion
- DIETARY_SUPPLEMENT Dietary nitrate
Study Locations (1)
Wisconsin
- University of Wisconsin La Crosse - La Crosse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
What NCT06420752 shows while recruiting
NCT06420752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (78% lower).
The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Calf Plantar flexion is the first listed.
NCT06420752 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06420752 about?
NCT06420752 is a clinical study titled "Passive Stretching in Peripheral Arterial Disease Patients". Peripheral artery disease (PAD) leads to higher mortality rates and strains healthcare systems due to increased costs. It causes leg pain during walking due to reduced blood flow. Nitric oxide (NO) deficiency contributes to vascular issues in PAD, with few effective treatments available. Passive cal...
What is the current status of trial NCT06420752?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2024-05-20. Estimated completion is 2029-12-31.
What conditions does trial NCT06420752 study?
This clinical trial studies the following conditions: Inflammation, Peripheral Arterial Disease, Walking, Difficulty.
What interventions are being tested in trial NCT06420752?
The interventions under investigation include: Calf Plantar flexion (DEVICE), Dietary nitrate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06420752?
This trial is sponsored by University of Wisconsin, La Crosse, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06420752 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06420752's enrollment target sits among peer trials
64 66th of 132 higher than 66 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI